This page is intended for investors only
Proveca is the future Engine of Children’s Medicine
Proveca is a Paediatric-focused pharmaceutical company that prioritises improving children’s lives through the provision and licensing of the right paediatric medicines.
Proveca has established a unique set of skills and expertise required for developing medicines for children.
Proveca is leading the way for developing medicines specifically for children. Proveca understands that healthcare providers and parents need confidence regarding the safety, efficacy, right dosage form and palatability of a medicine for a child. Therefore Proveca ensures all of its medicines are designed with the child in mind.
What sets us apart
Only children’s medicines
Proveca is focused solely on the development and licensing of children’s medicines. The team draws on many years of paediatric experience in formulation, regulatory, medical and commercial.
Proveca’s expertise in this area is valued by healthcare providers as we work with them to understand the problems associated with providing the right management and medications specifically for children.
Making a difference
Proveca are developing more than just the formulations, we conduct clinical trials to demonstrate the efficacy and safety of our medicines, as well as demonstrating the effects on quality of life. We aim to register them as widely as possible to benefit children all over the world.
Proveca also look to make a difference by helping to educate healthcare providers and carers about the conditions of importance to them and how the child can be managed effectively. To this end, Proveca has been providing an educational series to healthcare professionals and is co-ordinating the development of relevant European guidelines, which will help to educate and inform those who treat and manage chronically sick children.
Identifying the child’s unmet need
Working with clinicians, pharmacists, nurses, parents, and patients, Proveca is able to understand the problems around medications, such as lack of dose suitability or administration difficulty. As a result, Proveca’s research and development department are continuously looking at suitable formulation alternatives. This can involve looking to provide age appropriate dose forms, which improve palatability and adherence in order to improve symptom control and quality of life for the child and their carers.
Reaching children around the world
Proveca have a global ambition in the paediatric medicines market, which is valued at £100 billion per annum in the US, Canada, Europe and Japan.
Proveca aim to be the leading Children’s Pharmaceutical company in the world by 2030, aiming to licence and distribute to many countries and continents, to ensure children have global access to the right medications.
Latest news
Proveca and BCWorld Healthcare announce the launch of the first licensed product in South Korea
Published March 20 2026
Proveca and BCWorld Healthcare announce the launch of the first licensed product in South Korea for the symptomatic treatment of severe sialorrhea in children and adolescents aged 3 years and older with chronic neurological disorders.
Proveca Ltd submits a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Aqumeldi® (enalapril maleate), a prescription drug.
Published March 20 2026
Proveca Ltd submits a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Aqumeldi® (enalapril maleate), a prescription drug.
This press release is intended for investors only. Proveca Announces Exclusive Worldwide Development and License Agreement with Catalent for its Zydis® ODT Technology for use with Glycopyrrolate
Published February 10 2026
Proveca Announces Exclusive Worldwide Development and License Agreement with Catalent